Becton Dickinson & Co (NYSE: BDX)

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that specializes in the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. The company's offerings are used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. BD is a leading player in the medical technology industry, with a diverse portfolio of products and services that cater to various markets and customer segments.

The company's main business activities are categorized into three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces a range of medical technologies and devices that are used to improve healthcare delivery in various settings. This segment's products include medication delivery solutions, medication management solutions, and pharmaceutical systems. The primary customers served by BD Medical are hospitals and clinics, physicians, office practices, consumers and retail pharmacies, governmental and nonprofit public health agencies, pharmaceutical companies, and healthcare workers.

The BD Life Sciences segment provides products for the safe collection and transport of diagnostic specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections, and cancers. This segment's products are used by hospitals, laboratories, and clinics, as well as by blood banks, healthcare workers, physicians, office practices, retail pharmacies, academic and government institutions, and pharmaceutical and biotechnology companies.

The BD Interventional segment provides vascular, urology, oncology, and surgical specialty products that are intended to be used once and then discarded or are either temporarily or permanently implanted. This segment's products are used by hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via the company's Homecare business.

BD competes in a highly competitive industry, with companies of varying sizes competing in the global medical technology field. The company competes on the basis of many factors, including price, quality, innovation, service, reputation, distribution, and promotion. To remain competitive, BD invests in research and development, quality management, quality improvement, product innovation, manufacturing, and supply chain.

The company's products are marketed and distributed in the United States and internationally through independent distribution channels, as well as directly to hospitals and other healthcare-related institutions by BD and independent sales representatives. BD also collaborates with universities, medical centers, and other entities on research and development programs and retains individual consultants and partners to support its efforts in specialized fields.

BD is subject to various federal and state laws, and laws outside the United States, concerning healthcare fraud and abuse, global anti-corruption, transportation, safety and health, and customs and exports. The company is also subject to regulation by the U.S. Food and Drug Administration (FDA) and various other federal and state agencies, as well as by foreign governmental agencies. BD actively maintains quality systems that establish standards for its product design, manufacturing, and distribution processes, in accordance with ISO standards and FDA regulation.

In recent years, BD has faced several regulatory issues, including a consent decree with the FDA related to its infusion pump products, a Warning Letter from the FDA with respect to its former BD Preanalytical Systems unit, and a Form 483 Notice from the FDA with respect to its Medication Management Systems facility. The company has worked to address these issues and has implemented corrective actions to ensure compliance with regulatory requirements.

BD is a global company with a diverse workforce of approximately 73,000 associates located in over 62 countries. The company is committed to attracting, developing, and retaining talented people in all different functions. BD's ability to recruit and retain such talent depends on several factors, including compensation and benefits, talent development and career opportunities, and its unique culture. To that end, the company continually invests in its associates to be an employer of choice.

In addition to its commitment to diversity, equity, and inclusion, BD is also committed to associate growth and development. The company holds itself and its associates accountable for learning and growing every day, which underscores its growth mindset culture. BD offers associates and managers a robust offering of tools to help in their personal and professional development, including career development plans, mentoring programs, and in-house learning opportunities.

BD is also committed to associate engagement. The company believes it is critical that its associates are informed, engaged, and can provide feedback. BD communicates frequently and transparently with its associates through a variety of communication methods, including video and written communications, town hall meetings, associate surveys, and its company intranet. The company also acknowledges individual contributions to BD through a number of rewards and recognition award programs.